EAM
ENGN icon

Eventide Asset Management’s enGene Therapeutics ENGN Stock Holding History

Eventide Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-950,000
Closed -$8.58M – 286
2025
Q4 		$8.58M Buy
+950,000
New +$7.61M 0.13% 149

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Eventide Asset Management's ENGN Position: Q1 2026 in Review

Eventide Asset Management sold out of enGene Therapeutics (ENGN) in Q1 2026, closing a stake of 950,000 shares — an estimated $8.58M sold.

Eventide Asset Management first reported a position in ENGN in Q4 2025 and held it in 1 quarter. The position peaked at $8.58M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Eventide Asset Management reported no remaining enGene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Eventide Asset Management sold 950,000 enGene Therapeutics shares in Q1 2026, an estimated $8.58M.
  • Eventide Asset Management first reported a position in enGene Therapeutics in Q4 2025 and held it in 1 quarter.
  • Eventide Asset Management's enGene Therapeutics position peaked at $8.58M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.